

# Clinical trials of Enoximone

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 heart failure

| Trial   | Treatments  | Patients  | Trials design and methods  |
|---|---|---|--|
| <b>Enoximone vs placebo</b>   |   |   |  |
| <a href="#">Cowley , 1994</a><br>n=75/76<br>follow-up: 12 months  | Enoximone 300mg/d<br>versus<br>placebo                                | NYHA III,IV   | Parallel groups<br>double blind                                      |
| <a href="#">EMOTE , 2007</a><br>n=101/100<br>follow-up: 26 weeks  | enoximone<br>versus<br>placebo  | patients with ultra-advanced heart failure<br>requiring IV inotropic therapy  | Parallel groups<br>double blind<br>US                                |
| <a href="#">EMTG , 1990</a><br>n=50/52<br>follow-up: 4 months   | Enoximone <450 mg/d<br>versus<br>placebo                              | NYHA II, III  | Parallel groups<br>double blind                                      |
| <a href="#">ESG , 2000</a><br>n=70/35<br>follow-up: 3 months  | Enoximone 75-150 mg/d<br>versus<br>placebo                            | NYHA II, III  | Parallel groups<br>double blind                                      |
| <a href="#">ESSENTIAL (I and II) , 2009</a><br>[NCT00051285]<br>n=926/928<br>follow-up: 16.6 mo<br>(median) | enoximone titrated to 50 mg three times<br>daily<br>versus<br>placebo | Patients with New York Heart<br>Association class IIIIV HF symptoms, left<br>ventricular ejection fraction 30% , and one<br>hospitalization or two ambulatory visits<br>for worsening HF in the previous year | Parallel groups<br>double blind<br>Europe and North andSouth America |
| <a href="#">Lardoux , 1987</a><br>n=30/13<br>follow-up: 3 months  | Enoximone 150, 300mg/d<br>versus<br>placebo                           | NYHA NA   | Parallel groups<br>double blind                                      |
| <a href="#">WESG , 1991</a><br>n=108/56<br>follow-up: 3 months  | Enoximone 150, 300 mg/d<br>versus<br>placebo                          | NYHA II, III  | Parallel groups<br>double blind                                      |
| <b>enoximone vs placebo (on top metoprolol)</b>   |   |   |  |
| <a href="#">EMPOWER</a> <i>ongoing</i><br>[NCT00077948]<br>n=NA<br>follow-up:                               | enoximone<br>versus<br>placebo  | Advanced CHF Subjects Previously<br>Intolerant to Beta-Blocker Treatment  | Parallel groups<br>double blind                                      |

More details and results :

- phosphodiesterase III inhibitors for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q117>

## References

### **Cowley, 1994:**

Cowley AJ, Skene AM Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. Br Heart J 1994 Sep;72:226-30 [7946771]

### **EMOTE, 2007:**

Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J 2007 Nov;154:861-9 [17967591]

### **EMTG, 1990:**

Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990 Sep;82:774-80 [2144216]

### **ESG, 2000:**

Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, Dec GW, LeJemtel TH, Roden RL, Schleman MM, Robertson AD, Gorczynski RJ, Bristow MR Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol 2000;36:501-8 [10933364]

### **ESSENTIAL (I and II), 2009:**

Metra M, Eichhorn E, Abraham WT, Linseman J, Bhm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 2009 Dec;30:3015-26 [19700774]

### **Lardoux, 1987:**

Lardoux H, Trimarco B, Granier G, Marcadet O, Dubois-Rande JL, Multicentric, double blind and controlled study of oral enoximone (MDL 17043) in chronic heart failure. Circulation 1987;76(suppl IV):IV-179(abstr 0711).2

### **WESG, 1991:**

NEJM 1991;121:1471-1479 [7078592]

Narahara KA Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group. Am Heart J 1991 May;121:1471-9 [1826806]

### **EMPOWER, :**

ongoing trial NCT00077948

Entry terms: Fenoximone, Perfan, MDL 19438, MDL-17043, MDL 17043, MDL17043, , enoximone sulfoxide, MDL 17043 sulfoxide,